Arena’s obesity treatment, Belviq, received approval by the U.S. Food and Drug Administration this year, but the drug has yet receive a schedule from the Drug Enforcement Agency...
Worries that Vivus’ new obesity drug would not be widely covered by health insurers have been put to rest...
Here's why these healthcare stocks are moving now...
Here's why these health stocks are moving now...
The Nasdaq was down 0.65 percent on the day and strands at 3,116. These healthcare stocks helped to move the exchange...
It's always a good strategy to track transparency of pundits...
Arena’s weight-loss pill Belviq became the first obesity drug approved by the Federal Drug Administration since Xenical in 1999...
Analysts Lee Kalowski of Credit Suisse believes the stock represents an attractive "risk-reward profile"...
Arena Pharmaceuticals's Top Institutional Shareholders for Q2 2012
These stocks are attracting tons of trading interest now...
Here's the top trending stocks of the day ...
Analysis on highly active stocks for investors...
Here's the top trending stocks of the day ...
Here's what you need to know for the upcoming earnings release ...
Some hot headlines hitting the newswires this morning...